Vascepa Off-Label Communications Package Evolved With Lawsuit
This article was originally published in The Tan Sheet
Executive Summary
With the off-label promotion floodgates creaking open, NDA sponsors could begin to have more back and forths with FDA in court. A chart details proposals and counter-proposals from Amarin and FDA that led to final set of statements, materials and disclosures approved by the court.